Skip to main content

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.

Publication ,  Journal Article
Ditse, Z; Mkhize, NN; Yin, M; Keefer, M; Montefiori, DC; Tomaras, GD; Churchyard, G; Mayer, KH; Karuna, S; Morgan, C; Bekker, L-G; Mlisana, K ...
Published in: mSphere
January 29, 2020

Analysis of breakthrough HIV-1 infections could elucidate whether prior vaccination primes relevant immune responses. Here, we measured HIV-specific antibody responses in 14 South African volunteers who acquired HIV infection after participating in phase 1/2 trials of envelope-containing immunogens. Serum samples were collected annually following HIV-1 infection from participants in trials HVTN 073 (subtype C, DNA/MVA, phase 1 trial, n = 1), HVTN 086 (subtype C, DNA/MVA/gp140 protein, phase 1 trial, n = 2), and HVTN 204 (multisubtype, DNA/adenovirus serotype 5 [Ad5], phase 2 trial, n = 7) and 4 placebo recipients. Binding and neutralizing antibody responses to Env proteins and peptides were determined pre- and post-HIV infection using an enzyme-linked immunosorbent assay and the TZM-bl cell neutralization assay, respectively. HIV-infected South African individuals served as unvaccinated controls. Binding antibodies to gp41, V3, V2, the membrane-proximal external region (MPER), and the CD4 binding site were detected from the first year of HIV-1 subtype C infection, and the levels were similar in vaccinated and placebo recipients. Neutralizing antibody responses against tier 1A viruses were detected in all participants, with the highest titers being to a subtype C virus, MW965.26. No responses were observed just prior to infection, indicating that vaccine-primed HIV-specific antibodies had waned. Sporadic neutralization activity against tier 2 isolates was observed after 2 to 3 years of HIV infection, but these responses were similar in the vaccinated and placebo groups as well as the unvaccinated controls. Our data suggest that prior vaccination with these immunogens did not alter the antibody responses to HIV-1 infection, nor did it accelerate the development of HIV neutralization breadth.IMPORTANCE There is a wealth of information on HIV-specific vaccine-induced immune responses among HIV-uninfected participants; however, data on immune responses among participants who acquire HIV after vaccination are limited. Here we show that HIV-specific binding antibody responses in individuals with breakthrough HIV infections were not affected by prior vaccination with HIV envelope-containing immunogens. We also found that these vectored vaccines did not prime tier 2 virus-neutralizing antibody responses, which are thought to be required for prevention against HIV acquisition, or accelerate the development of neutralization breadth. Although this study is limited, such studies can provide insights into whether vaccine-elicited antibody responses are boosted by HIV infection to acquire broader neutralizing activity, which may help to identify antigens relevant to the design of more effective vaccines.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

mSphere

DOI

EISSN

2379-5042

Publication Date

January 29, 2020

Volume

5

Issue

1

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Viral Load
  • Neutralization Tests
  • Middle Aged
  • Male
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp41
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ditse, Z., Mkhize, N. N., Yin, M., Keefer, M., Montefiori, D. C., Tomaras, G. D., … Morris, L. (2020). Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. MSphere, 5(1). https://doi.org/10.1128/mSphere.00738-19
Ditse, Zanele, Nonhlanhla N. Mkhize, Michael Yin, Michael Keefer, David C. Montefiori, Georgia D. Tomaras, Gavin Churchyard, et al. “Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.MSphere 5, no. 1 (January 29, 2020). https://doi.org/10.1128/mSphere.00738-19.
Ditse Z, Mkhize NN, Yin M, Keefer M, Montefiori DC, Tomaras GD, et al. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29;5(1).
Ditse, Zanele, et al. “Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.MSphere, vol. 5, no. 1, Jan. 2020. Pubmed, doi:10.1128/mSphere.00738-19.
Ditse Z, Mkhize NN, Yin M, Keefer M, Montefiori DC, Tomaras GD, Churchyard G, Mayer KH, Karuna S, Morgan C, Bekker L-G, Mlisana K, Gray G, Moodie Z, Gilbert P, Moore PL, Williamson C, Morris L. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29;5(1).

Published In

mSphere

DOI

EISSN

2379-5042

Publication Date

January 29, 2020

Volume

5

Issue

1

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Viral Load
  • Neutralization Tests
  • Middle Aged
  • Male
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp41